OuiO will receive software security with this partnership for its Si One, for specialty drugs, and Si Pen, for diabetes patients. MedCrypt’s software will be able to sync with the drug delivery sensors to automatically send real-time dosing data. MedCrypt’s software will help monitor device usage for suspicious behavior. Encrypted and properly signed data will also be able to be communicated through ConnectedRx, QuiO’s cloud platform.
“It’s critical that our bi-directional communication channel remains secure at all times, from both a privacy and safety standpoint,” said QuiO co-founder and CEO Alexander Dahmani. “We’re proud to be working with MedCrypt because their technology has been successfully used to secure some of the highest-risk medical devices in the market and we want every available defense in today’s evolving cybersecurity landscape.”